Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05021536 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 25, 2021
Last Update Posted : January 6, 2023
|
Sponsor:
Amylyx Pharmaceuticals Inc.
Information provided by (Responsible Party):
Amylyx Pharmaceuticals Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Amyotrophic Lateral Sclerosis | Other: Placebo Drug: AMX0035 | Phase 3 |
AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow decline in function as measured by the ALSFRS-R and survival over 48 week. The trial will also assess the effects of AMX0035 on slow vital capacity, quality of life and plasma biomarkers of ALS.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 600 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS) |
| Actual Study Start Date : | October 28, 2021 |
| Estimated Primary Completion Date : | November 1, 2023 |
| Estimated Study Completion Date : | March 1, 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Amyotrophic lateral sclerosis
Juvenile primary lateral sclerosis
MedlinePlus related topics:
Amyotrophic Lateral Sclerosis
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
|
Other: Placebo
Matching Placebo Comparator |
|
Experimental: AMX0035
Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
|
Drug: AMX0035
Proprietary formulation of taurursodiol and sodium phenylbutyrate |
Primary Outcome Measures :
- Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope Change And Survival [ Time Frame: 48 weeks ]Change in slope of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) over treatment duration. The ALSFRS-R consists of 12 items across 4 subdomains of function (bulbar, fine motor, gross motor, and breathing) with each item scored on a scale from 0 (total loss of function) to 4 (no loss of function). Total scores range from 0 to 48, with higher scores indicating better function.
- Number of Participants With Adverse Events [ Time Frame: 48 weeks ]Comparison Between Groups of Number of Participants With Adverse Events Until Planned Completion
- Number of Participants in Each Group Able to Remain on Study Drug Until Planned Discontinuation [ Time Frame: 48 weeks ]A comparison o0f the number of participants in each group able to remain on study drug until planned discontinuation between groups
Secondary Outcome Measures :
- Rate of Decline in Slow Vital Capacity (SVC) [ Time Frame: 48 weeks ]Respiratory muscle function will be assessed according to slow vital capacity (SVC). SVC is measured in an upright position for at least three trials per assessment. SVC volumes will be standardized to the percentage of predicted normal value based on age, sex, and height.
- Participant Quality of Life (QOL) [ Time Frame: 48 weeks ]QOL will be measured using the 40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) patient-reported outcome (PRO)
- Decline in King's and MiToS Stages [ Time Frame: 48 weeks ]The decline in King's and MiToS (Milano-Torino staging) will be derived from ALSFRS-R data
- Ventilation Free Survival [ Time Frame: 48 weeks ]The composite outcome is defined as death, a death-equivalent event (tracheostomy), or hospitalization, whichever occurs first
- Participant Health Status [ Time Frame: 48 weeks ]Participant health status will be measured using the EQ-5D descriptive system and the EQ visual analogue scale [EQ VAS] patient reported outcomes questionnaire
- Assess Long-Term Survival [ Time Frame: 3 years ]Long-Term Survival will be obtained by monitoring of all-cause mortality
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female, at least 18 years of age
- Diagnosis of ALS (definite or clinically probable)
- Time since onset of first symptom of ALS should be <24 months prior to randomization;
- If the participant is to be treated with riluzole and/or edaravone during the course of the trial, then treatment with riluzole and/or edaravone was, at the time of the screening visit, started and maintained at a stable regimen for at least 14 days for riluzole and/or for a full treatment cycle for edaravone;
- Capable of providing informed consent
- Capable and willing to follow trial procedures including visits to the trial clinic and visit requirements;
- Women of child bearing potential (e.g. not post-menopausal for at least one year or surgically sterile) must agree to use adequate birth control for the duration of the study and 3 months after last dose of study drug. Women must not be planning to become pregnant for the duration of the study and 3 months after last dose of study drug
- Men must agree to practice contraception for the duration of the study and 3 months after last dose of study drug. Men must not plan to father a child or provide for sperm donation for the duration of the study and 3 months after last dose of study drug
Exclusion Criteria:
- Presence of tracheostomy or permanent assisted ventilation(PAV)
- Slow Vital Capacity (SVC) less than 55%
- History of known allergy to phenyl butyrate or bile salts
- Abnormal liver function defined as bilirubin levels and/or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 5 times the upper limit of the normal (obtained within 12 weeks from first dose)
- Renal insufficiency as defined by eGFR <60 mL/min/1.73m^2 (obtained within 12 weeks from first dose)
- Pregnant women (confirmed by a pregnancy test within 7 days of first dose) or women currently breastfeeding
- Current severe biliary disease which may result in the Investigator medical judgement in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gangrene of the gallbladder, abscess of the gallbladder
- History of Class III/IV heart failure (per New York Heart Association - NYHA)
- Participant under severe salt restriction where the added salt intake due to treatment would put the participant at risk, in the Investigator clinical judgment
- Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, according to Investigator judgment
- Clinically significant unstable medical condition (other than ALS) (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, severe laboratory test anomaly or clinically significant electrocardiogram [ECG] changes) that would pose a risk to the participant if he/she were to participate in the trial, according to Investigator judgment
- Previous treatment for ALS with cellular therapies or gene therapies
- Currently enrolled in another trial involving use of an investigational therapy
- Previous treatment with PB or taurursodiol within 30 days from Screening
- Implantation of Diaphragm Pacing System (DPS)
- Currently or previously treated within the last 30 days or planned exposure to any prohibited medications listed in Section 6.8 of the protocol
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05021536
Locations
Show 69 study locations
Sponsors and Collaborators
Amylyx Pharmaceuticals Inc.
| Responsible Party: | Amylyx Pharmaceuticals Inc. |
| ClinicalTrials.gov Identifier: | NCT05021536 |
| Other Study ID Numbers: |
A35-004 |
| First Posted: | August 25, 2021 Key Record Dates |
| Last Update Posted: | January 6, 2023 |
| Last Verified: | January 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Motor Neuron Disease Amyotrophic Lateral Sclerosis Sclerosis Pathologic Processes Neurodegenerative Diseases Nervous System Diseases |
Neuromuscular Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases |